More Than 65 Industry Players Across The World Are Presently Engaged In Evaluating The Clinical Applications Of Over 180 Cannabinoid-derivatives That Target The Human Endocannabinoid Signalling System

>

More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over 180 cannabinoid-derivatives that target the human endocannabinoid signalling system

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.

 

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:

  • Target Disease Indication
  • Cancer
  • Genetic Disorders
  • Neurological Indications
  • Others

 

  • Route of Administration
  • Oral
  • Inhalation

 

  • Key Geographies
  • North America
  • Europe

Asia-Pacific and the Rest of the World

 

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:

  • GW Pharmaceuticals
  • Corbus Pharmaceuticals
  • Tilray
  • Tetra Bio-Pharma
  • Botanix Pharmaceuticals
  • Kalytera Therapeutics
  • Therapix Biosciences
  • Echo Pharmaceuticals
  • Avicanna
  • GB Sciences

 

Table of Contents

 

  1. PREFACE

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

 

  1. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

 

  1. COMPANY PROFILES

 

  1. ACADEMIC GRANTS ANALYSIS

 

  1. PARTNERSHIPS AND COLLABORATIONS

 

  1. MERGERS AND ACQUISITIONS

 

  1. DRUG DEVELOPMENT STRATEGY ANALYSIS
  2. MARKET FORECAST AND OPPORTUNITY ANALYSIS

 

  1. CONCLUDING REMARKS

 

  1. EXECUTIVE INSIGHTS

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

 

 

Share:

Keywords: roots analysis,research,pharma,biotech,analysis,market research,industry reports,business report,global

Comments

Other related blogs

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

By : Roots Analysis

Roots Analysis has done a detailed report on Subcutaneous Biologics, Technologies and Drug..


The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030, predicts Roots Analysis

By : Roots Analysis

Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought..


Medical Device Labels Manufacturing Market, 2019-2030

By : Roots Analysis

To order this detailed 300+ page report, please visit this- https://www.rootsanalysis.com/reports/vi..